ÐÂÎÅ×ÊѶ
æÇÃÀGLP-1¶àëĹú¼ÊÃ÷ÐDzúÆ·£¡½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú¶àëÄÐÂÒ©ÔÚ·ÊÅÖÖÎÁÆÁìÓòÈ¡µÃÁÙ´²Ç°ÐÂÍ»ÆÆ
ÈÕÆÚ£º
2026Äê04ÔÂ02ÈÕ 14:40
ÔÚ·ÊÅÖ¼°Ïà¹Ø´úлÐÔ¼²²¡³ÉΪȫÇòÐÔ¿µ½¡Ìôսȷµ±Ï£¬£¬£¬ £¬£¬½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú£¨ÒÔϼò³Æ“½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú”£©´«À´Õñ·ÜÈËÐĵÄÐÂÎÅ£¡Æä×ÔÖ÷Ñз¢µÄÁ¢ÒìС·Ö×Ó»·ëÄÒ©ÎMCR»·ëÄ£©£¬£¬£¬ £¬£¬ÔÚÕë¶ÔDB/DB·ÊÅÖСÊóÄ£×ÓµÄÁÙ´²Ç°Ñо¿ÖУ¬£¬£¬ £¬£¬Õ¹ÏÖ³öÓÅÓÚÏÖÓÐÃ÷ÐÇÒ©ÎïGLP-1¶àëĵļõÖØЧ¹û£»£»£»£»£»£»£»ÍŽáÆä¶Ô¼¡ÈâµÄ¼á³Ö×÷Ó㬣¬£¬ £¬£¬ÒÔ¼°¶ÔѪÌÇ¡¢ÑªÖ¬µÈ´úлָ±êµÄ×ۺϵ÷Àí×÷Ó㬣¬£¬ £¬£¬ÓÐÍû´øÀ´²î±ð»¯µÄÁÙ´²Ñ¡Ôñ¡£¡£¡£¡£¡£
Ò»¡¢¾ªÑ޵ļõÖØÊý¾Ý
DB/DBСÊóÊÇÑо¿·ÊÅÖºÍ2ÐÍÌÇÄò²¡µÄ¾µä¶¯ÎïÄ£×Ó£¬£¬£¬ £¬£¬ÆäÓÉÓÚ»ùÒòÍ»±äµ¼ÖÂÊÝËØÊÜÌ幦ЧȱÏÝ£¬£¬£¬ £¬£¬ÌåÏÖ³öÑÏÖصķÊÅÖ¡¢¸ßѪÌǺʹúлÔÓÂÒµÈÖ¢×´¡£¡£¡£¡£¡£ÔÚ½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú¿ªÕ¹µÄÕâÏîÁÙ´²Ç°Ñо¿ÖУ¬£¬£¬ £¬£¬¹«Ë¾×ÔÑеÄС·Ö×Ó»·ëÄÕ¹ÏÖ³öÓÅÒìµÄ¼õÖØЧ¹û¡£¡£¡£¡£¡£
ÊÔÑéЧ¹ûÏÔʾ£¬£¬£¬ £¬£¬¾ÓÉΪÆÚ8ÖܵÄÖÎÁÆ£¬£¬£¬ £¬£¬Óë¿Õȱ±ÈÕÕ×éDB/DBСÊóÏà±È£¬£¬£¬ £¬£¬MCR»·ëĽϸ߼ÁÁ¿×éµÄСÊóµÄÌåÖØϽµ·ù¶ÈԼΪGLP-1¶àëÄ×éµÄ1.25±¶£¬£¬£¬ £¬£¬Ê¹DB/DBСÊóµÄÌåÖØÔöÌíÇ÷ÊÆÏÔ×Å·Å»º£¬£¬£¬ £¬£¬¿¿½ü¿µ½¡±ÈÕÕ×éˮƽ¡£¡£¡£¡£¡£
¶þ¡¢¶àÏî´úлָ±êÖÜÈ«¸ÄÉÆ
MCR»·ëĽϸ߼ÁÁ¿×éÔÚ¸ÄÉƸÊÓÍÈýõ¥£¨TG£©¡¢¸ßÃܶÈÖ¬ÂÑ°×µ¨¹Ì´¼£¨HDL-C£©¡¢ÑªÌÇ¡¢ÄòÌÇˮƽ·½Ã棬£¬£¬ £¬£¬Í¬ÑùÌåÏÖÓÅÒ죺
1.TGˮƽ£ºÏÔÖø½µµÍDB/DBСÊóµÄTGˮƽ£¬£¬£¬ £¬£¬ÓÅÓÚGLP-1¶àëÄ×飻£»£»£»£»£»£»
2.HDL-Cˮƽ£ºÏÔ×ÅÉý¸ß£¬£¬£¬ £¬£¬ÓÅÓÚGLP-1¶àëÄ×飻£»£»£»£»£»£»ÓÐÖúÓÚ½µµÍ¶¯ÂöÖàÑùÓ²»¯Î£º¦£»£»£»£»£»£»£»
3.ѪÌÇˮƽ£ºÖÎÁÆ6ÖܵĽµµÍѪÌÇŨ¶ÈˮƽÓëGLP-1¶àëÄ×é¿¿½ü£»£»£»£»£»£»£»
4.ÄòÌÇˮƽ£ºÖÎÁÆ8Öܽ«ÄòÌÇˮƽ´Ó»ùÏß½µÖÁÒ»°ë£»£»£»£»£»£»£»
5.ÌÇ»¯ÑªºìÂÑ°×£¨HbA1c£©£ºÓëÄ£×Ó×éÏà±È£¬£¬£¬ £¬£¬HbA1cϽµ·ù¶È´ïÔ¼1/3¡£¡£¡£¡£¡£
|ÍŽáDZÁ¦
ÖµµÃÒ»ÌáµÄÊÇ£¬£¬£¬ £¬£¬½ñÄê»á¹ÙÍøµÇ¼Èë¿ÚÒÑ¿ªÕ¹ÁË»·ëÄÓëGLP-1ÀàÒ©ÎÈçGLP-1¶àëÄ£©ÍŽáʹÓõÄÑо¿£¬£¬£¬ £¬£¬Ð§¹ûÏÔʾÔÚÒûʳÓÕµ¼µÄ·ÊÅÖСÊóÄ£×ÓÖУ¬£¬£¬ £¬£¬Á½ÕßÔÚ¼õÖØЧ¹û¼°¼¡Èâ±£»£»£»£»£»£»£»¤·½Ãæ¾ßÓÐÃ÷È·µÄÐͬЧӦ£º
1.Ðͬ¼õÖØ£ºÁªÊÊÓÃÒ©×éÌåÏÖ³ö¸üÏÔÖøµÄ¼õÖØЧ¹û£¬£¬£¬ £¬£¬ÓÅÓÚµ¥Ò©ÖÎÁÆ£»£»£»£»£»£»£»
2.ïÔ̼¡ÈâÁ÷ʧ£º»·ëÄÔÚÁªÓÃÖÐÓÐÓûº½âGLP-1ÀàÒ©Îï´øÀ´µÄ¼¡ÈâÁ÷ʧÎÊÌ⣬£¬£¬ £¬£¬Ìá¸ßÕûÌåÖÎÁÆÇå¾²ÐÔ¡£¡£¡£¡£¡£
Èý¡¢¶à°ÐµãÐͬ×÷Ó㺻·ëĵÄÁ¢Òì»úÖÆ
MCR»·ëÄÖ®ÒÔÊÇÄܹ»ÔÚ¼õÖؼ°ÆäËû´úлָ±êÉÏÈ¡µÃÔÆÔÆÓÅÒìµÄЧ¹û£¬£¬£¬ £¬£¬ÓëÆäÆæÒìµÄ×÷ÓûúÖÆÃܲ»¿É·Ö¡£¡£¡£¡£¡£×÷ΪһÖÖС·Ö×Ó»·ëÄÒ©Î£¬£¬ £¬£¬Äܹ»Í¬Ê±¾«×¼×÷ÓÃÓÚMC4RºÍMC1RÁ½¸öÒªº¦°Ðµã£¬£¬£¬ £¬£¬Í¨¹ý¶à°ÐµãÐͬ×÷Ó㬣¬£¬ £¬£¬Ê©Õ¹Æä׿ԽµÄ´úлµ÷Àí¹¦Ð§¡£¡£¡£¡£¡£
|¼¤»îMC4R£ºÒÖÖÆʳÓû£¬£¬£¬ £¬£¬Ôö½øÖ¬·¾ÆÊÎö
MC4RÊÇÖÐÊàÉñ¾ÏµÍ³µ÷¿ØÄÜÁ¿Æ½ºâµÄÒªº¦ÊÜÌå¡£¡£¡£¡£¡£½ñÄê»á¹ÙÍøµÇ¼Èë¿ÚMCR»·ëÄ×÷ΪMC4R¼¤¶¯¼Á£¬£¬£¬ £¬£¬Äܹ»Ôö½øÖ¬·¾ÆÊÎö£¬£¬£¬ £¬£¬ÒÖÖÆÖ¬·¾ÌìÉú£»£»£»£»£»£»£»Ôö½ø°×É«Ö¬·¾×éÖ¯ºÖ±ä£»£»£»£»£»£»£»Ìá¸ßÒȵºËØÃô¸ÐÐÔ£»£»£»£»£»£»£»ÔÚ²»ÏÔÖøÒÖÖÆʳÓûµÄÌõ¼þÏÂʵÏÖ¼õÖ¬£¬£¬£¬ £¬£¬×èÖ¹Ñáʳ¸±×÷ÓÃ1¡£¡£¡£¡£¡£
|¼¤»îMC1R:¿¹Ñ×ÃâÒßµ÷Àí£¬£¬£¬ £¬£¬»Ö¸´ÊÝËØÃô¸ÐÐÔ
MC1RÖ÷Òª¼ÓÈëÃâÒßµ÷ÀíºÍÑ×Ö¢·´Ó¦¡£¡£¡£¡£¡£Í¨¹ý¼¤»îMC1R£¬£¬£¬ £¬£¬Äܹ»ÏÔÖø¸ÄÉÆÌåÄÚÑ×֢΢ÇéÐΣ¬£¬£¬ £¬£¬½µµÍÑ×Ö¢Òò×Ó£¨°üÀ¨IL-1, TNF-a, IL-6, IL-8, and IL-12, iNOSµÈ£©µÄ±í´ï´Ó¶ø»Ö¸´ÊÝËØÃô¸ÐÐԺ͵÷ÀíÃâÒß·´Ó¦£¬£¬£¬ £¬£¬¶Ô×ÔÉíÃâÒßÐÔ¼²²¡¾ßÓÐDZÔÚÖÎÁƼÛÖµ2¡£¡£¡£¡£¡£
ËÄ¡¢ÁÉÀ«µÄÓ¦ÓÃÔ¶¾°£º´úлÔÓÂÒÓë×ÔÉíÃâÒß˳Ӧ֢
»ùÓÚMCR»·ëÄÔÚÁÙ´²Ç°Ñо¿ÖÐÕ¹ÏÖ³öµÄ׿Խ¼õÖØЧ¹ûºÍ¶àϵͳ´úл¸ÄÉÆ×÷Ó㬣¬£¬ £¬£¬½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú¶ÔÆäδÀ´ÔÚ´úлºÍ×ÔÃâÁìÓòÖеÄÓ¦ÓÃÔ¶¾°³äÂúÐÅÐÄ¡£¡£¡£¡£¡£
´úл×ÛºÏÕ÷¼°Æä²¢·¢Ö¢·½Ã棬£¬£¬ £¬£¬MCR»·ëIJ»µ«ÄܼõÖØ£¬£¬£¬ £¬£¬»¹ÄÜͬ²½¸ÄÉÆѪÌÇ¡¢ÑªÖ¬¡¢HbA1c¡¢ÄòÌǵȶàÏîÖ¸±ê£¬£¬£¬ £¬£¬¶Ô2ÐÍÌÇÄò²¡¡¢·Ç¾Æ¾«ÐÔÖ¬·¾ÐԸβ¡¡¢¸ßѪѹ¡¢¶¯ÂöÖàÑùÓ²»¯µÈ´úл×ÛºÏÕ÷×é·ÖÖ®Ò»»ò¶àÏî¾ßÓиÉԤDZÁ¦¡£¡£¡£¡£¡£
×ÔÉíÃâÒßÓëÑ×Ö¢Ïà¹Ø¼²²¡·½Ã棬£¬£¬ £¬£¬ÓÉÓÚÆä¾ß±¸ÏÔÖøµÄ¿¹Ñ׺ÍÃâÒßµ÷Àí×÷Ó㬣¬£¬ £¬£¬Î´À´ÓÐÍûÍØÕ¹ÖÁÀà·çʪÐÔÊàŦÑ×£»£»£»£»£»£»£»ÂýÐÔÉö²¡£¡£¡£¡£¡£¨CKD£©£»£»£»£»£»£»£»ÌÇÄò²¡Éö²¡£¡£¡£¡£¡£¨DN£©µÈ˳Ӧ֢¡£¡£¡£¡£¡£
½ÓÏÂÀ´£¬£¬£¬ £¬£¬¹«Ë¾½«¼ÌÐøÍƶ¯¶àëÄÐÂÒ©µÄÁÙ´²Ç°Ò©ÀíѧºÍ¶¾ÀíѧÑо¿£¬£¬£¬ £¬£¬ÕùÈ¡ÔçÈÕ½«ÐÂÒ©ÍÆÏòÁÙ´²½×¶Î£¬£¬£¬ £¬£¬ÔÚÒÑÊÚȨµÄרÀû¼Ó³ÖÏ£¬£¬£¬ £¬£¬¿ìËÙ½«²î±ð»¯µÄºÃÒ©´ø¸øÓµÓÐÏà¹ØÖÎÁÆÐèÇóµÄ»¼ÕßȺÌå¡£¡£¡£¡£¡£
ÎÄÕÂȪԴÓÚҩʱ´ú¹«ÖÚºÅ
²Î¿¼ÎÄÏ×
1. Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022). Signaling pathways in obesity: mechanisms and therapeutic interventions. Signal transduction and targeted therapy, 7(1), 298.https://doi.org/10.1038/s41392-022-01149-x
2. Mun, Y., Kim, W., & Shin, D. (2023). Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects. International journal of molecular sciences, 24(15),12152. https://doi.org/10.3390/ijms241512152
Ïà¹ØÍƼö
ÍøÕ¾½¨É裺ÖÐÆó¶¯Á¦ ̨ÖÝ